R&G PharmaStudies Co., Ltd. (SHE:301333)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2015	FY 2014	FY 2013
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
Medical Labs & Research	-	-	721.37M	637.52M	608.43M
Medical Labs & Research Growth	-	-	13.15%	4.78%	25.59%
Clinical Trial Technical Services	412.74M	375.09M	-	-	-
Clinical Trial Technical Services Growth	10.04%	-	-	-	-
Clinical Trial Related and Laboratory Services	438.27M	368.92M	-	-	-
Clinical Trial Related and Laboratory Services Growth	18.80%	-	-	-	-
Total	851.01M	744.00M	721.37M	637.52M	608.43M
Total Growth	14.38%	3.14%	13.15%	4.78%	25.59%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2015	FY 2014	FY 2013
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
China	779.64M	664.58M	674.39M	605.02M	576.29M
China Growth	17.31%	-1.45%	11.47%	4.98%	-
Overseas	71.37M	79.42M	46.98M	32.50M	32.13M
Overseas Growth	-10.14%	69.04%	44.57%	1.14%	-
Total	851.01M	744.00M	721.37M	637.52M	608.43M
Total Growth	14.38%	3.14%	13.15%	4.78%	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 14, 2026

Data Sources Report a data error